Ionis Pharmaceuticals, Inc. announced that topline results from the Phase 2b SOLANO study in patients with hypercholesterolemia demonstrated that 60mg of ION449 (AZD8233) administered...
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced the publication of positive Phase 2 data for donidalorsen (formerly IONIS-PKK-LRx) in the New England...
